Filsuvez Europska Unija - hrvatski - EMA (European Medicines Agency)

filsuvez

amryt pharmaceuticals dac - dry extract from birch bark (der 5-10 : 1), extraction solvent n-heptane 95% (w/w) - epidermolysis bullosa dystrophica; epidermolysis bullosa, junctional - pripravci za liječenje rana i ulkusa - treatment of partial thickness wounds associated with dystrophic and junctional epidermolysis bullosa (eb) in patients 6 months and older.

Episalvan Europska Unija - hrvatski - EMA (European Medicines Agency)

episalvan

amryt ag - betulae cortex - wounds and injuries; wound healing - pripravci za liječenje rana i ulkusa - liječenje rana djelomične debljine kod odraslih osoba. pogledajte odjeljke 4. 4 i 5. 1 u informacije o proizvodu s obzirom na vrstu rana koje se proučavaju.

Itulazax 12 SQ-Bet sublingvalni liofilizat Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

itulazax 12 sq-bet sublingvalni liofilizat

alk-abelló a/s, boge allé 6-8, horsholm, danska - standardizirani ekstrakt alergena peludi bijele breze - sublingvalni liofilizat - 12 sq-bet - urbroj: jedan sublingvalni liofilizat sadrži 12 sq-bet standardiziranog alergena ekstrakta peludi bijele breze (betula verrucosa)

NOBILIS IB 4-91 Hrvatska - hrvatski - Ministarstvo poljoprivrede, Uprava za Veterinarstvo i sigurnost hrane

nobilis ib 4-91

intervet international b.v., podružnica u republici hrvatskoj, heinzelova 62a, 10000 zagreb, hrvatska - živi, atenuirani virus zaraznog bronhitisa (soj 4-91) ≥3,6 log10 eid50 - liofilizat za resuspendiranje - kokoši

NOBILIS IB Ma5 Hrvatska - hrvatski - Ministarstvo poljoprivrede, Uprava za Veterinarstvo i sigurnost hrane

nobilis ib ma5

intervet international b.v., podružnica u republici hrvatskoj, ivana lučića 2a, 10000 zagreb, hrvatska - atenuirani virus zaraznog bronhitisa ptica (soj ma5) - liofilizat za suspenziju - kokoši

Abiraterone Accord Europska Unija - hrvatski - EMA (European Medicines Agency)

abiraterone accord

accord healthcare s.l.u. - abirateron acetat - prostatske neoplazme - endokrinska terapija - abiraterone accord is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mhspc) in adult men in combination with androgen deprivation therapy (adt)the treatment of metastatic castration resistant prostate cancer (mcrpc) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicatedthe treatment of mcrpc in adult men whose disease has progressed on or after a docetaxel based chemotherapy regimen.

Abiraterone Krka Europska Unija - hrvatski - EMA (European Medicines Agency)

abiraterone krka

krka, d.d., novo mesto - abirateron acetat - prostatske neoplazme - endokrinska terapija - abiraterone krka is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mhspc) in adult men in combination with androgen deprivation therapy (adt) (see section 5. 1)the treatment of metastatic castration resistant prostate cancer (mcrpc) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5. 1)the treatment of mcrpc in adult men whose disease has progressed on or after a docetaxel-based chemotherapy regimen.

Abiraterone Mylan Europska Unija - hrvatski - EMA (European Medicines Agency)

abiraterone mylan

mylan ireland limited - abirateron acetat - prostatske neoplazme - endocrine therapy, other hormone antagonists and related agents - abiraterone mylan is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mhspc) in adult men in combination with androgen deprivation therapy (adt). the treatment of metastatic castration resistant prostate cancer (mcrpc) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated. the treatment of mcrpc in adult men whose disease has progressed on or after a docetaxel based chemotherapy regimen.